Martindale-Hubbell Bar Register of Preeminent Lawyers Qui Tam Law Firm
Representing the rights of employees with knowledge of fraudulent conduct.
Leading American Attorneys
 Home | Steps to Whistleblowing | About Us | FAQ | Resources | False Claims Act | Retaining Our Firm | Respected Law Firm | Contact Us
Home > Government Reports > Medicare Payments For Enteral Nutrition > Recommendation
Medicare Payments For Enteral Nutrition

RECOMMENDATION

The findings of this report suggest that the supplier community obtains Category I enteral nutrition formula products at prices that are lower than Medicare’s reimbursement amount. If Medicare’s reimbursement amount had been based more closely on these prices, the program and its beneficiaries could have realized savings.

CMS had attempted to reduce Medicare payments for enteral nutrition formulas through the use of its inherent reasonableness authority. However, Congress suspended the use of the inherent reasonableness authority in the 1999 Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act before payment reductions could be implemented. In December 2002, CMS published an interim final rule on the use of inherent reasonableness authority. This rule, which became effective in February 2003, allows CMS contractors to raise or lower Medicare payment amounts for medical equipment and supplies by 15 percent in any given year without a formal rulemaking process.

We believe that continued CMS attention to Medicare Part B payments for Category I enteral nutrition formulas is warranted. Since CMS now has the authority to implement inherent reasonableness reductions, we recommend that CMS:

Consider using its inherent reasonableness authority to reduce the Medicare reimbursement amount for Category I enteral nutrition formulas.

CMS may want to begin an inherent reasonableness review by collecting information from Medicare suppliers to identify the specific Category I enteral nutrition formulas that suppliers provide to Medicare beneficiaries. CMS may also want to collect information from suppliers to determine suppliers’ purchase costs for the specific formulas used by Medicare beneficiaries.

Agency Comments
CMS agreed with our recommendation that it consider using inherent reasonableness authority to reduce the reimbursement amount for Category I formulas. CMS noted that it will not be able to initiate inherent reasonableness reviews until its contractor develops written procedures for conducting these reviews according to the statute and regulation.

Findings | Home | Appendices


Toll Free: 800-FRAUD 04
Do you think you have a claim? Contact Us

Nolan Law Firm - 435 North Andrews Avenue, Suite 401, Ft Lauderdale, FL 33301
Tel: (954) 779-3943 | Fax: (954) 779-3937
Toll free: 800-FRAUD 04
Licensed in the State of Florida - Available Nationally

Home | About Nolan Law Firm | Frequently Asked Questions | Whistleblower Resources
False Claims Act | Retaining Nolan Law Firm | A Respected Law Firm | Government Reports | Contact Nolan Law Firm

Overviews:
Qui Tam | Medicare Fraud | Health Care Fraud | Pharmaceutical Fraud
Site Map

The hiring of a lawyer is an important decision that should not be based solely on advertisements. Before you decide, ask us to send you free written information about our qualifications and experience.


Disclaimer | Copyright © 2006 Nolan Law Firm All Rights Reserved.
Qui Tam False Claims Act Cases - Site Map